

Molecular and Cellular Biomedical Sciences

Volume 2, Number 2, September 2018

REVIEW ARTICLES

Myokine Regulation as Marker of Sarcopenia in Elderly

I Gusti Putu Suka Aryana, Anak Agung Ayu Ratih Hapsari, Raden Ayu Tuty Kuswardhani; p.38-47

Ischemic Stroke: New Neuron Recovery Approach with Mesenchymal and Neural Stem Cells

Angliana Chouw, Rina Triana, Nurrani Mustika Dewi, Siska Darmayanti, Miftakh Nur Rahman, Ardian Susanto, Bayu Winata Putera, Cynthia Retna Sartika; p.48-54

RESEARCH ARTICLES

Survivin Ser81 Plays An Important Role in PI3K/Akt/mTOR Signaling Pathway

Ferry Sandra; p.55-9

Direct and Indirect Effect of $TNF\alpha$ and $IFN\gamma$ Toward Apoptosis in Breast Cancer Cells

Wahyu Widowati, Diana Krisanti Jasaputra, Sutiman Bambang Sumitro, Mochamad Aris Widodo, Ervi Afifah, Rizal, Dwi Davidson Rihibiha, Hanna Sari Widya Kusuma, Harry Murti, Indra Bachtiar, Ahmad Faried; p.60-9

No Association Between Lipid Profiles and Acne Vulgaris

Khairina Nasution, Imam Budi Putra, Nelva Karmila Jusuf; p.70-2

Print ISSN: 2527-4384

Online ISSN: 2527-3442

<https://www.cellbiopharm.com/ojs/index.php/MCBS>

Cell and
Biopharmaceutical
Institute



Molecular and Cellular Biomedical Sciences

MAILING ADDRESS

MCBS OFFICE

Prodia Tower 8F, Jl. Kramat Raya No.150, Jakarta Pusat 10430
Email: mcbs_office@cellbiopharm.com

PRINCIPAL CONTACT

Dr. Marshel Tendean
Phone: +62-81285043419
Email: dr.mars.23@gmail.com

SUPPORT CONTACT

Dr. Allen Weber
Email: mcbs_office@cellbiopharm.com

EDITOR IN CHIEF

Dr. Marshel Tendean
Department of Internal Medicine, Faculty of Medicine,
Krida Wacana Christian University, Indonesia

EDITORIAL BOARD

Prof. Akihiro Shimosaka
Hematology Institute, Peking Union Medical College, China

Prof. Anak Iamaron
Department of Oral Biology and Diagnostic Sciences,
Faculty of Dentistry, Chiang Mai University, Thailand

Dr. Bin Ren
Division of Hematology and Oncology, Department of Medicine,
Medical College of Wisconsin, United States of America

Prof. Hee Young Shin
Department of Pediatrics, Cancer Research Institute,
Seoul National University College of Medicine, South Korea

Prof. Hiroyuki Kumamoto
Division of Oral Pathology, Department of Oral Medicine and Surgery,
Graduate School of Dentistry, Tohoku University, Japan

Dr. Ines Atmosukarto
College of Medicine, Biology & Environment,
Australian National University, Australia

Dr. Irawan Satriotomo
Center for Translational Research in Neurodegenerative Disease (CTRND),
University of Florida, United States of America

Dr. Laifa Annisa Hendamin
Section of Biology, Faculty of Medicine and Health Sciences,
Syarif Hidayatullah State Islamic University, Indonesia

Dr. Mutsumi Miyauchi
Department of Oral and Maxillofacial Pathobiology, Basic Life Sciences,
Institute of Biomedical and Health Sciences, Hiroshima University, Japan

Dr. Thai Yen Ling
Department of Pharmacology,
College of Medicine, National Taiwan University, Taiwan

Dr. Wahyu Widowati
Department of Biology,
Faculty of Medicine, Maranatha Christian University, Indonesia

Prof. Yen Hua Huang
Department of Biochemistry and Molecular Cell Biology,
Graduate Institute of Medical Sciences College of Medicine,
Taipei Medical University, Taiwan

Dr. Yudi Her Oktaviono
Department of Cardiology and Vascular Medicine,
Faculty of Medicine / Dr. Soetomo Hospital, Airlangga University, Indonesia

FOCUS AND SCOPE

Molecular and Cellular Biomedical Sciences (MCBS) is an open access, peer-reviewed journal that supports all topics in Biology, Pathology, Pharmacology, Biochemistry, Histology and Biomedicine in the aspect of molecular and cellular.

MCBS is dedicated to publish review and research articles. The editors will carefully select manuscript to be delivered for peer-reviewing process. Therefore MCBS is committed to present only the valuable and recent scientific findings.

SECTION POLICIES

REVIEW ARTICLE

Review Article should consist of no more than 10,000 words, not including the words in abstract, references, table, figure, and figure legend. The manuscript should have no more than six figures and/or tables in total and no more than 200 references.

RESEARCH ARTICLE

Research Article should consist of no more than 3,500 words, not including the words in abstract, references, table, figure, and figure legend. The manuscript should have no more than six figures and/or tables in total and no more than 40 references.

PEER REVIEW PROCESS

All manuscripts submitted to Molecular and Cellular Biomedical Sciences will be selected and blind peer-reviewed by 2 or more reviewers when necessary, to present valuable and authentic findings. All details will also be reviewed, including appropriate title; content reflecting abstract; concise writing; clear purpose, study method and figures and/or tables; and summary supported by content. The reviewing process will take generally 2-3 months depends on sufficiency of information provided.

Peer-reviewers were selected based on their specialties that fit to the topic. Additional reviewer/s can also be pointed when necessary. Author can suggest reviewer/s that not having publication together within five years and should not be member/s of the same research institution.

PUBLICATION FREQUENCY

Molecular and Cellular Biomedical Sciences is published biannually (in March and September).

OPEN ACCESS POLICY

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

ARCHIVING

This journal utilizes the LOCKSS system to create a distributed archiving system among participating libraries and permits those libraries to create permanent archives of the journal for purposes of preservation and restoration.

Molecular and Cellular Biomedical Sciences

PLAGIARISM SCREENING POLICY

All manuscripts submitted to Molecular and Cellular Biomedical Sciences will be screened for plagiarism by using Grammarly.

CONTENT LICENSING

All materials are free to be copied and redistributed in any medium or format. However, appropriate credit should be given. The material may not be used for commercial purposes. This content licensing is in accordance with a CC license: CC-BY-NC

CONFLICT OF INTEREST POLICY

AUTHOR'S CONFLICT OF INTEREST

At the point of submission, Molecular and Cellular Biomedical Sciences requires that each author reveal any personal and/or financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications, or opinions stated. When considering whether you should declare a conflicting interest or connection, please consider the conflict of interest test: Is there any arrangement that would embarrass you or any of your co-authors if it was to emerge after publication and you had not declared it? Corresponding authors are responsible to confirm whether they or their co-authors have any conflicts of interest to declare, and to provide details of these. The statement includes any information regarding whether the manuscript is under consideration for other publication, or whether you have any patents that relevant to the manuscript. If the manuscript is published, any conflict of interest information will be written in the Conflict of Interest statement.

AUTHOR'S ACKNOWLEDGEMENT

Authors whose manuscripts are submitted for publication must declare all relevant sources of funding in support of the preparation of a manuscript. Molecular and Cellular Biomedical Sciences requires full disclosure of financial support as to whether it is from government agencies, the pharmaceutical or any other industry, or any other source. Authors are required to specify sources of funding for the study and to indicate whether or not the manuscript was reviewed by the sponsor prior to submission. This information should be included in the Acknowledgements section of the manuscript. In addition to disclosure of direct financial support to the authors or their laboratories and prior sponsor-review of the paper, corresponding authors will be asked to disclose all relevant consultancies since the views expressed in the contribution could be influenced by the opinions they have expressed privately as consultants. This information should also be included in the Acknowledgments section of the manuscript.

REVIEWER'S CONFLICT OF INTEREST

Reviewers must disclose to editors any conflicts of interest that could bias their opinions of the manuscript, and should recuse themselves from reviewing specific manuscripts if the potential for bias exists. As in the case of authors, silence on the part of reviewers concerning potential conflicts may mean either that such conflicts exist that they have failed to disclose, or that conflicts do not exist. Reviewers must not use information of the manuscript they are reviewing before it is being published, to further their own interests.

PROTECTION OF HUMAN SUBJECT AND ANIMAL IN RESEARCH POLICY

When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the World Medical Association Declaration of Helsinki. If doubt exists whether the research was conducted in accordance with the said declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

When reporting experiments on animals, authors should be asked to indicate whether the institutional and national guide for the care and use of laboratory animals was followed. Further guidance on animal research ethics is available from the International Association of Veterinary Editors' Consensus Author Guidelines on Animal Ethics and Welfare.

INFORMED CONSENT POLICY

Patients have a right to privacy that should not be violated without informed consent. Identifying information, including names, initials, or hospital numbers, should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Authors should disclose to these patients whether any potential identifiable material might be available via internet as well as in print after publication. Nonessential identifying details should be omitted.

Molecular and Cellular Biomedical Sciences decides that patient confidentiality is better guarded by having the authors archive the consent, and instead providing us with a written statement in the manuscript attesting that they have received and archived written patient consent. When informed consent has been obtained, it should be indicated later in the published article.

ROLE OF JOURNAL EDITOR

Editors of Molecular and Cellular Biomedical Sciences have responsibilities toward the authors who provide the content of the journals, the peer reviewers who comment on the suitability of manuscripts for publication, also toward the journal's readers and the scientific community. Editors are responsible for monitoring and ensuring the fairness, timeliness, thoroughness, and civility of the peer-review and other editorial processes.

Peer review by external reviewers with the proper expertise is the most common method to ensure manuscript quality. However, our editors may sometimes reject manuscripts without external peer review to make the best use of their resources. Reasons for this practice are usually that the manuscript is outside the scope of Molecular and Cellular Biomedical Sciences, does not meet our quality standards or lacks originality or novel information.

Editor Responsibilities toward Authors

- Providing guidelines to authors for preparing and submitting manuscripts
- Providing a clear statement of the Journal's policies on authorship criteria
- Treating all authors with fairness, courtesy, objectivity, honesty, and transparency
- Establishing and defining policies on conflicts of interest for all involved in the publication process, including editors, staff, authors, and reviewers
- Protecting the confidentiality of every author's work
- Establishing a system for effective and rapid peer review
- Making editorial decisions with reasonable speed and communicating them in a clear and constructive manner
- Being vigilant in avoiding the possibility of editors and/or referees delaying a manuscript for suspect reasons
- Establishing a procedure for reconsidering editorial decisions
- Describing, implementing, and regularly reviewing policies for handling ethical issues and allegations or findings of misconduct by authors and anyone involved in the peer review process
- Informing authors of solicited manuscripts that the submission will be evaluated according to the journal's standard procedures or outlining the decision-making process if it differs from those procedures
- Clearly communicating all other editorial policies and standards

Editor Responsibilities toward Reviewers

- Assigning papers for review appropriate to each reviewer's area of interest and expertise
- Establishing a process for reviewers to ensure that they treat the manuscript as a confidential document and complete the review promptly
- Informing reviewers that they are not allowed to make any use of the work described in the manuscript or to take advantage of the knowledge they gained by reviewing it before publication
- Providing reviewers with written, explicit instructions on the journal's expectations for the scope, content, quality, and timeliness of their reviews to promote thoughtful, fair, constructive, and informative critique of the submitted work
- Requesting that reviewers identify any potential conflicts of interest and asking that they recuse themselves if they cannot provide an unbiased review
- Allowing reviewers appropriate time to complete their reviews
- Requesting reviews at a reasonable frequency that does not overtask any reviewer

Molecular and Cellular Biomedical Sciences

- Finding ways to recognize the contributions of reviewers, for example, by publicly thanking them in the journal; providing letters that might be used in applications for academic promotion; offering professional education credits; or inviting them to serve on the editorial board of the journal
- Making final decision regarding a submission status after receiving review result from reviewers

Editor Responsibilities toward Readers and the Scientific Community

- Evaluating all manuscripts considered for publication to make certain that each provides the evidence readers need to evaluate the authors' conclusions and that authors' conclusions reflect the evidence provided in the manuscript
- Providing literature references and author contact information so interested readers may pursue further discourse
- Requiring the corresponding author to review and accept responsibility for the content of the final draft of each paper
- Maintaining the journal's internal integrity (e.g., correcting errors; clearly identifying and differentiating types of content, such as reports of original data, corrections/errata, retractions, supplemental data, and promotional material or advertising; and identifying published material with proper references)
- Ensuring that all involved in the publication process understand that it is inappropriate to manipulate citations by, for example, demanding that authors cite papers in the journal
- Disclosing all relevant potential conflicts of interest of those involved in considering a manuscript or affirming that none exist
- Working with the publisher to attract the best manuscripts and research that will be of interest to readers

AUTHOR GUIDELINES

1. General Terms

Molecular and Cellular Biomedical Sciences welcomes articles covering all aspects of biomedical sciences. All submitted manuscripts must not be previously published and not under consideration for publication elsewhere. Papers may come from any country but must be written in English. The manuscript may be submitted as review articles, research articles, and short communications. There are no submission and processing charges for this journal.

All manuscripts are subjected to peer review. All submissions must be accompanied by abstracts of the authors' manuscripts on related subjects that are in press or under editorial review. Electronic reprints of related published papers by the author/s or manuscripts in the press also may be helpful to the reviewers.

All manuscripts must be accompanied by a covering letter signed by all author/s. Upon acceptance, author/s must transfer copyright to Cell and BioPharmaceutical Institute (CBPI). Accepted papers become the permanent property of CBPI and may be used according to copyright policy, or for particular purposes, please contact CBPI. It is the author/s' responsibility to obtain permission to reproduce illustrations, tables, etc. from other publication.

2. How to Submit

Authors are required to submit manuscripts electronically by using online journal system cellbiopharm.com/ojs.

3. Requirements of Each Manuscript Type

Review Article: Review Article should consist of no more than 10,000 words, not including the words in abstract, references, table, figure, and figure legend. The manuscript should have no more than six figures and/or tables in total and no more than 200 references.

Research Article: Research Article should consist of no more than 3,500 words, not including the words in abstract, references, table, figure, and figure legend. The manuscript should have no more than six figures and/or tables in total and no more than 40 references.

4. Abstract

Provide an abstract of no more than 300 words (for Review Article) or 250 words (for Research Article). Structured-abstract should be followed in writing Research Article.

5. References

- References should be according to the Vancouver system.
- List all authors when there are six or fewer; when there are seven or more, list the first six, followed by "et al."
- A sequential number of references in the main text. Please follow in detail all examples below:

Article:

Sandra F, Esposti MD, Ndebele K, Gona P, Knight D, Rosenquist M, et al. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Alters Mitochondrial Membrane Lipids. *Cancer Res.* 2005; 65(18): 8286-97.

Book

Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. *Medical microbiology*. 4th ed. St. Louis: Mosby; 2002.

Chapter in a book:

Arlaukas SP. Near infrared fluorescent choline kinase alpha inhibitors for cancer imaging and therapy [Dissertation]. Philadelphia: University of Pennsylvania; 2015. p.335-58.

Dissertation/Thesis/Essay:

Arlaukas SP. Near infrared fluorescent choline kinase alpha inhibitors for cancer imaging and therapy [Dissertation]. Philadelphia: University of Pennsylvania; 2015.

Part of Website/Monograph:

Medline Plus [Internet]. Bethesda: US National Library of Medicine; ©2009. Diabetic Kidney Problems [update 2015 Nov 2; cited 2015 Nov 16]. Available from: <https://www.nlm.nih.gov/medlineplus/diabetickidneyproblems.html>.

Conference Paper:

Fledelius HS. Myopia and significant visual impairment: global aspects. In: Lin LLK, Shin YF, Hung PT, editors. *Myopia Updates II: Proceedings of the 7th International Conference on Myopia 1998 Nov 17-20, Taipei*. Tokyo: Springer; 2000. p.3-17.

6. Unit of Measurement

- Authors can express all measurements in Conventional or International System (SI) units.
- Drug names must use generic names. When proprietary brands are used in research, include the brand name, the name and location (city & country) of the manufacturer in parentheses after the first mention of the generic name.

SUBMISSION PREPARATION CHECKLIST

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

1. The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
2. The submission file is in OpenOffice, Microsoft Word, RTF, or WordPerfect document file format. Formatted as standard A4 page setup.
3. Where available, URLs for the references have been provided.
4. The text should be double-spaced with the 1-inch margin on the left and right sides. Use 12-point Times New Roman font.
5. The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines, which is found in About the Journal.
6. Running title provided (not more than 8 words).
7. Proof of permission was obtained to reproduce illustrations, tables, etc. from other publication.
8. Complete information about author/s (first, middle, last name), author/s affiliation, and email address of the corresponding author.
9. All pages are numbered at bottom right.

COPYRIGHT NOTICE

For the submission of a manuscript to Molecular and Cellular Biomedical Sciences, I hereby certify that:

1. I have been granted authorization by my co-author/s to enter into these arrangements.
2. I hereby declare, on behalf of myself and my co-author/s, that:
 - The manuscript submitted is an original work and has neither been published in any other peer-reviewed journal nor is under consideration for publication by any other journal. More so, the work has been carried out in the author/s' lab and the manuscript does not contravene any existing copyright or any other third party rights.

Molecular and Cellular Biomedical Sciences

- I am/we are the sole author/s of the manuscript and maintain the authority to enter into this agreement and the granting of rights to the publisher: The Cell and BioPharmaceutical Institute (CBPI), does not infringe any clause of this agreement.
- The manuscript contains no such material that may be unlawful, defamatory, or which would, if published, in any way whatsoever, violate the terms and conditions as laid down in the agreement.
- I/we have taken due care that the scientific knowledge and all other statements contained in the manuscript conform to true facts and authentic formulae and will not, if followed precisely, be detrimental to the user.
- I/we permit the adaptation, preparation of derivative works, oral presentation or distribution, along with the commercial application of the work.
- No responsibility is assumed by Molecular and Cellular Biomedical Sciences (MCBS) and CBPI, its staff or members of the editorial boards for any injury and/or damage to persons or property as a matter of

products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in a publication by MCBS.

Copyright:

Author/s who publish in any MCBS print & online journal will transfer copyright to their work to CBPI. Submission of a manuscript to the respective journals implies that all author/s have read and agreed to the content of the Covering Letter or the Terms and Conditions. It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Plagiarism is strictly forbidden, and by submitting the manuscript for publication the author/s agree that the publishers have the legal right to take appropriate action against the author/s, if plagiarism or fabricated information is discovered. By submitting a manuscript, the author/s agree that the copyright of their manuscript is transferred to CBPI, if and when the manuscript is accepted for publication. Once submitted to the journal, the author/s will not withdraw their manuscript at any stage prior to publication. However, the copyright will be released to author/s when the manuscript is rejected.

Molecular and Cellular Biomedical Sciences

CONTENT

REVIEW ARTICLES

Myokine Regulation as Marker of Sarcopenia in Elderly

I Gusti Putu Suka Aryana, Anak Agung Ayu Ratih Hapsari, Raden Ayu Tuty Kuswardhani
p.38-47

Ischemic Stroke: New Neuron Recovery Approach with Mesenchymal and Neural Stem Cells

Angliana Chow, Rina Triana, Nurrani Mustika Dewi, Siska Darmayanti, Miftakh Nur Rahman, Ardian Susanto, Bayu Winata Putera, Cynthia Retna Sartika
p.48-54

RESEARCH ARTICLES

Survivin Ser81 Plays An Important Role in PI3K/Akt/mTOR Signaling Pathway

Ferry Sandra
p.55-9

Direct and Indirect Effect of $TNF\alpha$ and $IFN\gamma$ Toward Apoptosis in Breast Cancer Cells

Wahyu Widowati, Diana Krisanti Jasaputra, Sutiman Bambang Sumitro, Mochamad Aris Widodo, Ervi Afifah, Rizal, Dwi Davidson Rihibiha, Hanna Sari Widya Kusuma, Harry Murti, Indra Bachtiar, Ahmad Faried
p.60-9

No Association Between Lipid Profiles and Acne Vulgaris

Khairina Nasution, Imam Budi Putra, Nelva Karmila Jusuf
p.70-2

RESEARCH ARTICLE

MCBS

Mol Cell Biomed Sci. 2018; 2(2): 55-9
DOI: 10.21705/mcbs.v2i2.2**Survivin Ser81 Plays An Important Role in PI3K/Akt/mTOR Signaling Pathway**Ferry Sandra^{1,2}¹*Department of Biochemistry and Molecular Biology, Division of Oral Biology, Faculty of Dentistry, Universitas Trisakti, Jakarta, Indonesia*²*BioCORE Laboratory, Faculty of Dentistry, Universitas Trisakti, Jakarta, Indonesia*

Background: Survivin, a member of the inhibitor of apoptosis protein family, has been associated with protection from cell apoptosis and regulation of mitosis. Phosphorylated-Survivin at Ser81 was reported to provide cytoprotection against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) in L929 cells by inducing a backloop activation of phosphatidylinositol 3-kinase (PI3K). Therefore Akt as a possible substrate of PI3K was investigated.

Materials and Methods: L929 cells were pretreated with/without 50 μ M LY294002 or 10 μ M Perifosine, and infected with viral particle of Survivin, anti sense of Survivin, Ser81Ala mutated Survivin or vector only. Cells were then harvested, lysed and subjected to immunoblot assay to detect Akt, phosphorylated Akt (Ser473), mammalian target of rapamycin (mTOR), phosphorylated-mTOR (Ser2448).

Results: Survivin induced Akt and mTOR phosphorylations in a viral particle concentration dependent manner. Pretreatment of LY294002 or Perifosine prior to Survivin infection, attenuated Akt or mTOR phosphorylations, respectively. Low Akt or mTOR phosphorylations were observed when L929 cells were infected with Ser81Ala mutated Survivin.

Conclusions: Ser81 phosphorylation site of Survivin played an important role in activating Survivin/PKA/PI3K/Akt/mTOR signaling pathway.

Keywords: survivin, Ser81, Akt, mTOR, LY294002, perifosine

Introduction

Survivin, a member of the inhibitor of apoptosis protein family, has been associated with protection from cell apoptosis and regulation of mitosis.^{1,2} In most finally differentiated adult tissues, Survivin expression is low to undetectable.^{1,2} However, Survivin is overexpressed in advanced cancers pertaining to poor prognosis, high recurrence and resistance to therapy.^{1,2} Survivin was reported

to be involved in all tumor stages, started from initiation, maintenance, until development of tumor.¹ Therefore, anti-survivin has been suggested as a new approach for cancer therapy.^{1,2}

Survivin has been shown to play role in multiple² and back-loop³⁻⁵ signaling pathways. Survivin could be activated due to its phosphorylation at Thr34⁶ and Ser8^{13,7,8}. Among many other molecules, cyclin B1 and p34^{cdc2} were reported in activation of Survivin at Thr34⁶, while protein

Date of submission: March 30, 2017
Last Revised: April 18, 2017
Accepted for publication: April 18, 2017

Corresponding Author:

Ferry Sandra
Department of Biochemistry and Molecular Biology, Division of Oral Biology
Faculty of Dentistry, Universitas Trisakti, Jl. Kyai Tapa No.260
Jakarta, Indonesia
E-mail: ferrysandra@gmail.com



Cell and
Biopharmaceutical
Institute



kinase A (PKA) and phosphatidylinositol 3-kinase (PI3K) were reported in activation of Survivin at Ser8^{13,7,8}. Survivin phosphorylation can also occur at Thr53, Thr117 and Ser20.⁹ Inhibition of Survivin phosphorylation by PH domain leucine-rich repeat protein phosphatase (PHLPP) induces cell apoptosis and exerts anticancer activity in gallbladder cancer.⁹

To date, Survivin has been shown to induce vascular endothelial growth factor (VEGF)/PI3K/Akt,⁴ PKA/PI3K,³ and PI3K/Akt/hypoxia-inducible factor (HIF)-1 α signaling pathways¹⁰. However phosphorylation of Survivin, as the key role of Survivin activation has not been intensely investigated. Phosphorylation of Survivin at Thr34^{6,11} was the mostly investigated, other important phosphorylation sites were Thr117¹² and Ser8^{13,7,8}. Ser81 of Survivin was reported to provide cytoprotection against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) in L929 cells.⁷ Survivin Ser81 was reported to be important in back-loop Survivin/PKA/PI3K signaling pathway.³ Since Akt was reported as the substrate of PI3K in overexpressed-Survivin model⁴, current study was initiated to investigate the possibility of Akt as the downstream of PKA/PI3K in Survivin phosphorylation at Ser81-modulated L929 cells.

Materials and methods

Survivin constructs, viral production and L929 cells infection

Preparation of Survivin, Antisense Survivin (Survivin-AS) and Ser81Ala mutants (Survivin-S81A) were described in our previous report.¹⁻³ Briefly, Survivin, Survivin-AS, Survivin-S81A mutants cDNAs were polymerased, inserted into vector and transfected into BOSC23 cells. BOSC23 cells-produced viruses were harvested and tittered. L929 cells were cultured in α -DMEM containing 10% horse serum. Infection was carried out using viral product of BOSC23 cells (Survivin, Survivin-AS, Survivin-S81A or vector only) for 48 hours.

Cell treatment and lysate preparation

L929 cells were pretreated with/without 50 μ M LY294002 (Cell Signaling, Danvers, MA, USA) or 10 μ M Perifosine (Cell Signaling), and infected with viral particle of Survivin, Survivin-AS, Survivin-S81A or vector only. Cells were then harvested and lysed in a cold lysis buffer (20 mM Tris-HCl buffer pH 8.0, 500 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM β -glycerophosphate, 10 mM NaF, 10 mM pNPP, 0.4 mM

Na₃VO₄, 1 mM benzamidine, 2 mM phenylmethylsulfonyl fluoride, aprotinin, 1 mg/ml leupeptin, 1 mM dithiothreitol and 10% Nonidet P-40).

Immunoblot assay

Samples were separated by SDS-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride sheet. After blocking with 5% skim milk in Tris-buffered saline, the sheet was incubated with rabbit polyclonal anti-Akt (Cell Signaling), rabbit polyclonal anti-phospho-Akt (Ser473) (Cell Signaling), rabbit polyclonal anti-mammalian target of rapamycin (mTOR) (Cell Signaling) or rabbit polyclonal anti-phospho-mTOR (Ser2448) (Cell Signaling) antibody. The secondary antibody was horseradish peroxidase-conjugated goat anti-rabbit IgG antibody (Cell Signaling). The bound antibodies were visualized using Clarity Western ECL (Bio-Rad, Hercules, CA, USA) and captured using Alliance 4.7 (UVitech, Cambridge, UK).

Results

Survivin induced Akt phosphorylation

In Figure 1, basal Akt phosphorylation (Ser473) band of L929 cells (upper lane 1 from left) was seen. Upon Survivin infection in concentration of 7.5x10⁷ viral particle/ml, density of Akt phosphorylation (Ser473) band was increased (upper lane 3 from left). Density of Akt phosphorylation (Ser473) band was increased markedly when the cells were infected with Survivin in concentration of 75x10⁷ viral particle/ml (upper lane 4 from left). Similar band densities of Akt were observed for all lower lanes, showing that the same volume of proteins were electrophorated and detected.




Figure 1. Survivin induced Akt phosphorylation. L929 cells were infected with/without 1.5-75x10⁷ viral particle/ml retrovirus of Survivin for 48 hours. Infected cells were then lysed and immunoblotted using anti-Akt or anti-phospho-Akt (Ser473) antibody. Detailed procedures are described in "Materials and Methods". Each panel shows the typical result of 3 independent results.

Survivin induced Akt phosphorylation via PI3K

In Figure 2, high density bands of Akt phosphorylation (Ser473) were observed when L929 cells were infected with 75x10⁷ viral particle/ml retrovirus of Survivin with/

without pretreatment of DMSO (upper lane 4 and 2 from left, respectively). Meanwhile, pretreatment of LY294002 prior to infection with 75×10^7 viral particle/ml retrovirus of Survivin, resulted a low density band of Akt phosphorylation (Ser473) (upper lane 3 from left). Similar band densities of Akt were observed for all lower lanes, showing that the same volume of proteins were electrophorated and detected.




Figure 2. Survivin induced Akt phosphorylation via PI3K. L929 cells were pretreated with/without 50 μ M LY294002 for 2 hours prior to infection with/without 75×10^7 viral particle/ml retrovirus of Survivin for 48 hours as indicated in the panel. Cells were lysed and immunoblotted using anti-Akt or anti-phospho-Akt (Ser473) antibody. DMSO was used as negative control. Detailed procedures are described in "Materials and Methods". Each panel shows the typical result of 3 independent results.

Survivin Ser81 in Akt phosphorylation

Low density bands of Akt phosphorylation (Ser473) were observed when L929 cells were not infected, infected with vector merely, infected with 75×10^7 viral particle/ml retrovirus of Survivin-AS and infected with 75×10^7 viral particle/ml retrovirus of Survivin-S81A, as shown in Figure 3 (upper lane 1, 2, 4 and 5 from left, respectively). Meanwhile, a high density band of Akt phosphorylation (Ser473) was observed when L929 cells were infected with 75×10^7 viral particle/ml retrovirus of Survivin (upper lane 3 from left). Similar band densities of Akt were observed for all lower lanes, showing that the same volume of proteins were electrophorated and detected.




Figure 3. Survivin Ser81 in Akt phosphorylation. L929 cells were infected with 75×10^7 viral particle/ml retrovirus of Survivin, Survivin-AS, Survivin-S81A or vector merely for 48 hours. Infected cells were then lysed and immunoblotted using anti-Akt or anti-phospho-Akt (Ser473) antibody. Detailed procedures are described in "Materials and Methods". Each panel shows the typical result of 3 independent results.

Survivin induced mTOR phosphorylation via Akt

In Figure 4, density of mTOR phosphorylation (Ser2448) band was increased upon Survivin infection in concentration of 7.5×10^7 viral particle/ml (upper lane 3 from left). Density of mTOR phosphorylation (Ser2448) band was increased markedly when the cells were infected with Survivin in concentration of 75×10^7 viral particle/ml (upper lane 4 from left). A high density band of mTOR phosphorylation (Ser2448) was also observed when L929 cells were infected with 75×10^7 viral particle/ml retrovirus of Survivin with pretreatment of ethanol (upper lane 6 from left). Meanwhile, pretreatment of Perifosine prior to infection with 75×10^7 viral particle/ml retrovirus of Survivin, resulted a low density band of mTOR phosphorylation (Ser2448) (upper lane 5 from left). Similar band densities of mTOR were observed for all lower lanes, showing that the same volume of proteins were electrophorated and detected.




Figure 4. Survivin induced mTOR phosphorylation via Akt. L929 cells were pretreated with/without 10 μ M Perifosine for 1 hour prior to infection with/without 1.5- 75×10^7 viral particle/ml retrovirus of Survivin for 48 hours as indicated in the panel. Cells were lysed and immunoblotted using anti-mTOR or anti-phospho-mTOR (Ser2448) antibody. Detailed procedures are described in "Materials and Methods". Ethanol was used as negative control. Each panel shows the typical result of 3 independent results.

Survivin Ser81 in mTOR phosphorylation

Low density bands of mTOR phosphorylation (Ser2448) were observed when L929 cells were not infected, infected with vector merely, infected with 75×10^7 viral particle/ml retrovirus of Survivin-AS and infected with 75×10^7 viral particle/ml retrovirus of Survivin-S81A, as shown in Figure 5 (upper lane 1, 2, 4 and 5 from left, respectively). Meanwhile, a high density band of mTOR phosphorylation (Ser2448) was observed when L929 cells were infected with 75×10^7 viral particle/ml retrovirus of Survivin (upper lane 3 from left). Similar band densities of mTOR were observed for all lower lanes, showing that the same volume of proteins were electrophorated and detected.




Figure 5. Survivin Ser81 in mTOR phosphorylation. L929 cells were infected with 75×10^7 viral particle/ml retrovirus of Survivin, Survivin-AS, Survivin-S81A or vector merely for 48 hours. Infected cells were then lysed and immunoblotted using anti-mTOR or anti-phospho-mTOR (Ser2448) antibody. Detailed procedures are described in "Materials and Methods". Each panel shows the typical result of 3 independent results.

Discussion

Current results showed that Survivin induced Akt phosphorylation at Ser473 in a concentration dependent manner. By pretreatment of LY294002, a PI3K inhibitor, the Akt phosphorylation was diminished, suggesting that PI3K was the upstream of Survivin-induced Akt phosphorylation. These results were in accordance to previous reports,^{4,10} that Survivin induced PI3K/Akt signaling pathway. In vector-infected and Survivin-AS-infected L929 cells, the Akt phosphorylation bands were not clearly seen, showing that the phosphorylation was induced specifically by Survivin. In addition, Akt phosphorylation was not clearly seen in Survivin S81A-infected L929 cells, showing that Ser81 phosphorylation site of Survivin is important in this signaling pathway.

PI3K/Akt constitute an important pathway regulating the signaling of multiple biological processes such as apoptosis, metabolism, cell proliferation and cell growth.^{13,14} Components related to PI3K/Akt pathway have been reported widely as causal factors in cancer.¹³⁻¹⁵ Activation of PI3K and Akt are reported to occur in breast, ovarian, blood, pancreatic, esophageal, gallbladder and other cancers.^{13,14}

mTOR, one of the downstream of Akt, has been widely reported. PI3K/Akt/PTEN/mTOR signaling pathway plays a crucial role in regulating a broad range of cellular functions including cell growth, proliferation, cell survival, angiogenesis, invasion and migration, apoptosis, autophagy, cell cycle, DNA repair, chemoresistance and radioresistance in cancer cells.¹⁶ PI3K converts PIP_2 into PIP_3 ,¹³ then Akt will be attracted by PIP_3 and phosphorylated by phosphoinositide-dependent protein kinase (PDK), which subsequently causes alteration of numerous cell functions including the activation of mTOR and its substrates.¹⁶

Current results showed that Survivin induced mTOR phosphorylation at Ser2448 in a concentration dependent manner. By pretreatment of Perifosine, an Akt inhibitor, the mTOR phosphorylation was diminished, suggesting that Akt was the upstream of Survivin-induced mTOR phosphorylation. In Survivin S81A-infected L929 cells, the mTOR phosphorylation bands were not clearly seen as well.

Previously we reported that Survivin induced PKA/PI3K.^{3,8} Hence, by combining with current results, we suggest signaling pathway of Survivin/PKA/PI3K/Akt/mTOR. This signaling pathway could serve as a survival pathway in L929 cells that attenuated TRAIL's potential in inducing apoptosis.⁷ In addition Ser81 phosphorylation site of Survivin played an important role in activating the signaling pathway. Taken together, our current results suggest that Ser81 Survivin play an important role in inducing PKA/PI3K/Akt/mTOR survival signaling pathway. Further investigation is necessary to disclose other potential downstream of Survivin/PKA/PI3K-regulated Akt.

References

1. Athanasoula KCh, Gogas H, Polonifi K, Vaiopoulos AG, Polyzos A, Mantzourani M. Survivin Beyond Physiology: Orchestration of Multistep Carcinogenesis and Therapeutic Potentials. *Cancer Lett.* 2014; 347(2): 175-82.
2. Altieri DC. Survivin - The inconvenient IAP. *Semin Cell Dev Biol.* 2015; 39: 91-6.
3. Sandra F, Khosravi-Far R. Phosphorylated-survivin at Ser81 Induced Protein Kinase A (PKA): A Back Loop. *Indones Biomed J.* 2011; 3(2): 138-42.
4. Fernández JG, Rodríguez DA, Valenzuela M, Calderon C, Urzúa U, Munroe D, *et al.* Survivin Expression Promotes VEGF-induced Tumor Angiogenesis via PI3K/Akt Enhanced β -catenin/Tcf-Lef Dependent Transcription. *Mol Cancer.* 2014; 13: 209. doi: 10.1186/1476-4598-13-209.
5. Sanhueza C, Wehinger S, Castillo Bennett J, Valenzuela M, Owen GI, Quest AF. The Twisted Survivin Connection To angiogenesis. *Mol Cancer.* 2015; 14: 198. doi: 10.1186/s12943-015-0467-1.
6. Zhou S, Li L, Jian X, Ou X, Jiang H, Yao Z, *et al.* The Phosphorylation of Survivin Thr34 by p34cdc2 in Carcinogenesis of Oral Submucous Fibrosis. *Oncol Rep.* 2008; 20(5): 1085-91.
7. Sandra F, Khosravi-Far R. Survivin S81A Enhanced TRAIL's Activity in Inducing Apoptosis. *Indones Biomed J.* 2010; 2(3): 113-7.
8. Sandra F, Khosravi-Far R. Ser81 Survivin Induced Protein Kinase A (PKA)-dependent Phosphatidylinositol 3-Kinase (PI3K) Activity. *Indones Biomed J.* 2014; 6(3): 157-62.
9. Qiu Y, Li X, Yi Bin, Zheng J, Peng Z, Zhang Z, *et al.* Protein Phosphatase PHLPP Induces Cell Apoptosis and Exerts Anticancer Activity by Inhibiting Survivin Phosphorylation and Nuclear Export in Gallbladder Cancer. *Oncotarget.* 2015; 6(22): 19148-62.
10. Ma WH, Liu YC, Xue ML, Zheng Z, Ge YL. Downregulation of Survivin Expression Exerts Antitumoral Effects on Mouse Breast Cancer Cells *in vitro* and *in vivo*. *Oncol Lett.* 2016; 11(1): 159-167.

11. Pannone G, Bufo P, Serpico R, Rubini C, Zamparese R, Corsi F, *et al.* Survivin Phosphorylation and M-phase Promoting Factor in Oral Carcinogenesis. *Histol Histopathol.* 2007; 22(11): 1241-9.
12. Delacour-Larose M, Thi MN, Dimitrov S, Molla A. Role of Survivin Phosphorylation by Aurora B in Mitosis. *Cell Cycle.* 2007; 6(15): 1878-85.
13. Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, More Than the AKT Pathway. *Carcinogenesis.* 2007; 28(7): 1379-86.
14. Zhang S, Yu D. PI(3)king Apart PTEN's Role in Cancer. *Clin Cancer Res.* 2010; 16(17): 4325-30.
15. Lunardi A, Webster KA, Papa A, Padmani B, Clohessy JG, Bronson RT, *et al.* Role of Aberrant PI3K Pathway Activation in Gallbladder Tumorigenesis. *Oncotarget.* 2014; 5(4): 894-900.
16. Chang L, Graham PH, Ni J, Hao J, Bucci J, Cozzi PJ, *et al.* Targeting PI3K/Akt/mTOR Signaling Pathway in The Treatment of Prostate Cancer Radioresistance. *Crit Rev Oncol Hematol.* 2015; 96(3): 507-17.